TY - JOUR
T1 - Recommendations for Dermatology Office Reopening in the Era of COVID-19
AU - Arruda, Suleima
AU - Hexsel, Doris
AU - Lim, Tingsong
AU - Waldorf, Heidi A.
AU - Artzi, Ofir
AU - Choi, WHosung
AU - Ghannam, Sahar
AU - Gaomin, Huang
AU - Ho, Wilson
AU - Puyat, Maria Cristina
AU - Rossi, Elena
AU - Shamban, Ava
AU - Sattler, Sonja
AU - Sadick, Neil
N1 - Publisher Copyright:
© 2020 Journal of Drugs in Dermatology. All rights reserved.
PY - 2020/7
Y1 - 2020/7
N2 - The COVID-19 pandemic, originating in Wuhan, China, has become a major public health and economic challenge for countries around the world. As of May 08, 2020, there are over 3 million COVID-19 cases, and 250,000 COVID-19- associated deaths in 215 countries. As more data is collected, updated infection control measures are continuously released and published by government, public health authorities, and physician specialty associations. Across the globe, dermatological practices have had to limit their operations to varying degrees to facilitate disease control, but as the pandemic Dosubsides, Not they Copy will broaden their operations. In light of the uncertainty surrounding safe and effective practice of medical and aesthetic dermatology in the era of COVID-19, fourteen international experts in the field contributed to recommendations for effective infection Penalties control protocols Apply and practice management modifications. While guidance from the World Health Organization and local public health officials comes first, these recommendations are crafted as a starting point for dermatologists worldwide to commence either reopening their doors to patients or expanding available service offerings. This can help ensure that patients receive needed care in the short term and improve long term practice viability.
AB - The COVID-19 pandemic, originating in Wuhan, China, has become a major public health and economic challenge for countries around the world. As of May 08, 2020, there are over 3 million COVID-19 cases, and 250,000 COVID-19- associated deaths in 215 countries. As more data is collected, updated infection control measures are continuously released and published by government, public health authorities, and physician specialty associations. Across the globe, dermatological practices have had to limit their operations to varying degrees to facilitate disease control, but as the pandemic Dosubsides, Not they Copy will broaden their operations. In light of the uncertainty surrounding safe and effective practice of medical and aesthetic dermatology in the era of COVID-19, fourteen international experts in the field contributed to recommendations for effective infection Penalties control protocols Apply and practice management modifications. While guidance from the World Health Organization and local public health officials comes first, these recommendations are crafted as a starting point for dermatologists worldwide to commence either reopening their doors to patients or expanding available service offerings. This can help ensure that patients receive needed care in the short term and improve long term practice viability.
UR - http://www.scopus.com/inward/record.url?scp=85088851837&partnerID=8YFLogxK
U2 - 10.36849/JDD.2020.5293
DO - 10.36849/JDD.2020.5293
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 32726557
AN - SCOPUS:85088851837
SN - 1545-9616
VL - 19
SP - E1-E9
JO - Journal of Drugs in Dermatology
JF - Journal of Drugs in Dermatology
IS - 7
ER -